Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. It provides contrast agents, such as Iohexol injection, Gadolinol injection, Gadopentetate Dimeglumine injection, Iodixanol injection, and Iopamidol injection; Jiuweizhenxin granule, a central nervous system product; and oral anti-diabetic drugs, including Glimepiride tablets and Repaglinide tablets. The company was founded in 1992 and is based in Beijing, China.
Frequently asked questions
What sector does Beijing Beilu Pharmaceutical (300016) operate in?
Beijing Beilu Pharmaceutical belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Beijing Beilu Pharmaceutical (300016) current stock price?
As of the latest data, Beijing Beilu Pharmaceutical stock price is CN¥8.75, with a previous close of CN¥8.62. Beijing Beilu Pharmaceutical gained CN¥0.13 in the last trading session, representing a 1.51% increase.
What is Beijing Beilu Pharmaceutical (300016) current market capitalization?
Beijing Beilu Pharmaceutical market cap is approximately 5.09 billion.
What is Beijing Beilu Pharmaceutical (300016) Earnings Per Share (EPS)?
The trailing EPS is CN¥0.23.
What is Beijing Beilu Pharmaceutical (300016) Price-to-Earnings (P/E) ratio?
Beijing Beilu Pharmaceutical current P/E ratio is 38.04.
Does Beijing Beilu Pharmaceutical (300016) pay dividends?
No. Beijing Beilu Pharmaceutical does not pay a dividend.
What is Beijing Beilu Pharmaceutical (300016) beta (volatility) score?
Beijing Beilu Pharmaceutical has a beta of 0.285, indicating lower volatility than the overall market.